ReviewDeutsches Arzteblatt international2020
Epidemiological Measures in the Context of the COVID-19 Pandemic.
Review in Deutsches Arzteblatt international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Identification of methodological issues regarding direct impact indicators of COVID-19: a rapid scoping review on morbidity, severity and mortality.European journal of public health · 2024Article
- Application of distributed lag models and spatial analysis for comparing the performance of the COVID-19 control decisions in European countries.Scientific reports · 2023Article
- Prevalence of and factors associated with a treatment delay due to the COVID-19 pandemic in patients with gastrointestinal cancer in Europe.Journal of cancer research and clinical oncology · 2023Article
- High variability of COVID-19 case fatality rate in Germany.BMC public health · 2023Article
- Estimation and prediction of the multiply exponentially decaying daily case fatality rate of COVID-19.The Journal of supercomputing · 2023Article
- Spatial-temporal trends of COVID-19 infection and mortality in Sudan.Scientific reports · 2022Article
- [SARS-CoV-2, influenza and norovirus infection : A direct epidemiologic comparison].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2022Article
- [Explaining the age-adjusted excess mortality with COVID-19-attributed deaths from January 2020 to July 2021].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2022Article
- [Epidemiological approaches to address key research questions on COVID-19-an overview].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2021Review
- Health Sufficiency Indicators for Pandemic Monitoring.International journal of environmental research and public health · 2021Article
- A Framework for the Community Psychiatrist's Role in the COVID-19 Response.Community mental health journal · 2021Article
- Modern Burden of Disease Studies as a Basis for Decision-Making Processes in Public Health.Deutsches Arzteblatt international · 2021Article
- Gender specific excess mortality in Italy during the COVID-19 pandemic accounting for age.European journal of epidemiology · 2021Article
- The Epidemiological and Spatiotemporal Characteristics of the 2019 Novel Coronavirus Disease (COVID-19) in Libya.Frontiers in public health · 2021Article
- Article
- A Retrospective Analysis of the Initial Effect of COVID-19 on German Prehospital Care During Lockdown in Germany.Open access emergency medicine : OAEM · 2021Article
- Standardized Mortality Ratios.Deutsches Arzteblatt international · 2020Article
- In Reply.Deutsches Arzteblatt international · 2020Article
- [Management of Diagnostic Procedures and Treatment of Sleep Related Breathing Disorders in the Context of the Coronavirus Pandemic - German Respiratory Society (DGP), German Sleep Society (DGSM)].Pneumologie (Stuttgart, Germany) · 2020Article
- Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe various epidemiological indicators used to communicate the impact of COVID-19 have different strengths and limitations.
methodsWe conducted a selective literature review to identify the indicators used and to derive appropriate definitions. We calculated crude and age-adjusted indicators for selected countries.
resultsThe proportion of deaths (case fatality proportion [CFP]; number of deaths/ total number of cases) is commonly used to estimate the severity of a disease. If the CFP is used for purposes of comparison, the existence of heterogeneity in the detection and registration of cases and deaths has to be taken into account. In the early phase of an epidemic, when case numbers rise rapidly, the CFP suffers from bias. For these reasons, variants have been proposed: the "confirmed CFP" (number of deaths/total number of confirmed cases), and the "delay-adjusted CFP," which considers the delay between infection with the disease and death from the disease. The indicator mortality (number of deaths/total population) has at first sight the advantage of being based on a defined denominator, the total population. During the outbreak of a disease, however, the cumulative deaths rise while the total population remains stable. The phase of the epidemic therefore has to be considered when using this indicator. In this context, R0 and R(t) are important indicators. R0 estimates the maximum rate of spread of a disease in a population, while R(t) describes the dynamics of the epidemic at a given time. Age-adjusted analysis of the CFP shows that the differences between countries decrease but do not dis - appear completely. If the test strategies depend on age or symptom severity, however, the bias cannot be entirely eliminated.
conclusionVarious indicators of the impact of the COVID-19 epidemic at population level are used in daily communication. Considering the relevance of the pandemic and the importance of relevant communications, however, the strengths and the limitations of each parameter must be considered carefully.
Indexed as
Identifiers
32527379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.